Durvalumab vs Trimethaphan Camsylate

Durvalumab vs Trimethaphan Camsylate: Overview

This comparison examines the pharmacological differences between Durvalumab and Trimethaphan Camsylate.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Durvalumab — 17 days.

Chemical Properties

Type: Durvalumab — Antibody; Trimethaphan Camsylate — Small molecule.